

## **Gemphire to Present at Two Investor Conferences**

March 8, 2018 8:00 AM ET

LIVONIA, Mich., March 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that management will be making presentations at the 30<sup>th</sup> Annual ROTH Conference and the H.C. Wainwright 2<sup>nd</sup> Annual NASH Investor Conference.

### ***Presentation Details***

#### ***30<sup>th</sup> Annual ROTH Conference***

Date: Tuesday, March 13  
Time: 7am Pacific Time/10am Eastern Time  
Panel: It Is Not a Myth, It Is Real: Pediatric NASH  
Panelist: Seth Reno, Chief Commercial Officer  
Location: Ritz Carlton, Laguna Niguel, California

Date: Tuesday, March 13  
Time: 8am Pacific Time/11am Eastern Time  
Panel: Love Your Liver, Love Your Heart: Cardio-Metabolic Molecules  
Panelist: Steve Gullans, Ph.D., Interim Chief Executive Officer  
Location: Ritz Carlton, Laguna Niguel, California

#### ***H.C. Wainwright 2<sup>nd</sup> Annual NASH Investor Conference***

Date: Monday, March 19  
Time: 8:40am Eastern Time  
Presenter: Steve Gullans, Ph.D., Interim Chief Executive Officer  
Location: St. Regis Hotel, New York City  
Webcast: <http://wsw.com/webcast/hcw3/gemp/>

### **About Gemphire**

Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire's Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit [www.gemphire.com](http://www.gemphire.com) for more information.

### **Contact:**

Andrew McDonald, Ph.D.  
LifeSci Advisors, LLC  
(646) 597-6987

Jeff Mathiesen, CFO  
Gemphire Therapeutics Inc.

(734)-245-1700

 [Primary Logo](#)

Gemphire Therapeutics Inc.